Martingale Asset Management’s 10x Genomics TXG Stock Holding History

Martingale Asset Management’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.28M	Sell	59,375 -25,832	-30%	-$677K	0.05%	366
2026 Q1	$1.81M	Sell	85,207 -3,799	-4%	-$75.9K	0.05%	366
2025 Q4	$1.45M	Buy	89,006 +3,003	+3%	+$45.4K	0.04%	391
2025 Q3	$1.01M	Buy	86,003 +14,301	+20%	+$186K	0.03%	479
2025 Q2	$830K	Buy	+71,702	New	+$654K	0.02%	510
2023 Q2	–	Sell	-11,921	Closed	-$665K	–	874
2023 Q1	$665K	Buy	11,921 +3	+0%	+$140	0.01%	549
2022 Q4	$434K	Buy	11,918 +3,314	+39%	+$108K	0.01%	646
2022 Q3	$246K	Buy	+8,604	New	+$328K	﹤0.01%	747
2021 Q2	–	Sell	-23,019	Closed	-$4.17M	–	901
2021 Q1	$4.17M	Sell	23,019 -21,613	-48%	-$3.73M	0.05%	207
2020 Q4	$6.32M	Buy	+44,632	New	+$6.48M	0.07%	207

Other funds holding TXG

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

QCM

Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Martingale Asset Management's TXG Position: Q2 2026 in Review

Martingale Asset Management reduced its 10x Genomics (TXG) stake by 30% in Q2 2026, selling an estimated $677K and leaving 59,375 shares worth $2.28M. The position accounts for 0.05% of the portfolio, ranked #366.

Martingale Asset Management first reported a position in TXG in Q4 2020 and has held it in 10 quarters since. The position peaked at $6.32M in Q4 2020. 390 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

Martingale Asset Management held 59,375 shares of 10x Genomics worth $2.28M as of Q2 2026.
Martingale Asset Management sold 25,832 10x Genomics shares in Q2 2026, an estimated $677K.
10x Genomics made up 0.05% of Martingale Asset Management's portfolio in Q2 2026, its #366 holding.
Martingale Asset Management first reported a position in 10x Genomics in Q4 2020 and has held it in 10 quarters since.
Martingale Asset Management's 10x Genomics position peaked at $6.32M in Q4 2020.
390 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on Martingale Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.